EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtLeitlinie

Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022

Eiki Ichihara, Nobuaki Ochi, Go Makimoto, Kenichiro Kudo, Daijiro Harada, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama und 16 weitere

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02469-4 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Eiki Ichihara und 27 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Oncology, Okayama University Hospital, 2-5-1 Shikata-Cho Kita-Ku, Okayama City,, 700-8558, Japan. ichiha-e@md.okayama-u.ac.jp. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Granulocyte colony-stimulating factor (G-CSF) is commonly administered to cancer patients undergoing myelosuppressive chemotherapy, especially when incidence rate of febrile neutropenia (FN) surpasses 20%. While primary prophylaxis with G-CSF has been proven effective in preventing FN in patients with cancer, there is limited evidence regarding its efficacy in specifically, lung cancer. Our systematic review focused on the efficacy of G-CSF primary prophylaxis in lung cancer. METHODS: We extracted studies on non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) using the PubMed, Ichushi Web, and Cochrane Library databases. Two reviewers assessed the extracted studies for each type of lung cancer and conducted quantitative and meta-analyses of preplanned outcomes, including overall survival, FN incidence, infection-related mortality, quality of life, and musculoskeletal pain. RESULTS: A limited number of studies were extracted: two on NSCLC and six on SCLC. A meta-analysis was not conducted owing to insufficient data on NSCLC. Two case-control studies explored the efficacy of primary prophylaxis with G-CSF in patients with NSCLC (on docetaxel and ramucirumab therapy) and indicated a lower FN frequency with G-CSF. For SCLC, meta-analysis of five studies showed no significant reduction in FN incidence, with an odds ratio of 0.38 (95% confidence interval 0.03-5.56, P = 0.48). Outcomes other than FN incidence could not be evaluated due to low data availability. CONCLUSION: Limited data are available on G-CSF prophylaxis in lung cancer. Primary prophylaxis with G-CSF may be weakly recommended in Japanese patients with NSCLC undergoing docetaxel and ramucirumab combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaHumansGranulocyte Colony-Stimulating FactorDocetaxelQuality of LifeRamucirumabAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

G-CSFNon-small-cell lung cancerSmall-cell lung cancer

Substanzen

Granulocyte Colony-Stimulating FactorDocetaxelRamucirumab

Autor:innen und Institutionen

  • Center for Clinical Oncology, Okayama University Hospital, 2-5-1 Shikata-Cho Kita-Ku, Okayama City,, 700-8558, Japan. ichiha-e@md.okayama-u.ac.jp.
  • Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
  • Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
  • Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan.
  • Department of Thoracic Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan.
  • Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Zitieren

APA

Ichihara, E., Ochi, N., Makimoto, G., Kudo, K., Harada, D., Ozaki, Y., Nishio, H., Tsuchihashi, K., Miura, Y., Endo, M., Yano, S., Maruyama, D., Yoshinami, T., Susumu, N., Takekuma, M., Motohashi, T., Ito, M., Baba, E., Uchino, K., …, & Kubo, T. (2024). Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02469-4

Vancouver

Ichihara E, Ochi N, Makimoto G, Kudo K, Harada D, Ozaki Y, et al. Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02469-4

BibTeX
@article{Ichihara2024,
  author = {Ichihara, Eiki and Ochi, Nobuaki and Makimoto, Go and Kudo, Kenichiro and Harada, Daijiro and Ozaki, Yukinori and Nishio, Hiroshi and Tsuchihashi, Kenji and Miura, Yuji and Endo, Makoto and Yano, Shingo and Maruyama, Dai and Yoshinami, Tetsuhiro and Susumu, Nobuyuki and Takekuma, Munetaka and Motohashi, Takashi and Ito, Mamoru and Baba, Eishi and Uchino, Keita and Kimura, Takahiro and Kamiyama, Yutaro and Nakao, Shinji and Tamura, Shinobu and Nishimoto, Hitomi and Kato, Yasuhisa and Sato, Atsushi and Takano, Toshimi and Kubo, Toshio},
  title = {Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02469-4}
}
Kostenlos starten →